Briocia Pharma (India ) Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
as on 22-06-2024
- Paid Up Capital ₹ 1.20 Cr
as on 22-06-2024
- Company Age 22 Year, 9 Months
- Last Filing with ROC 30 Jun 2013
- Open Charges ₹ 26.73 Cr
as on 22-06-2024
- Satisfied Charges ₹ 12.30 Cr
as on 22-06-2024
About Briocia Pharma (India )
The Corporate was formerly known as Briocia Pharma (India ) Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 30 June 2013. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 1.20 Cr.
The company currently has active open charges totaling ₹26.73 Cr. The company has closed loans amounting to ₹12.30 Cr, as per Ministry of Corporate Affairs (MCA) records.
Abhay Kapse, Avinash Chandvankar, and Gopal Ramourti serve as directors at the Company.
- CIN/LLPIN
U24230MH2002PLC135088
- Company No.
135088
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
07 Mar 2002
- Date of AGM
29 Dec 2013
- Date of Balance Sheet
30 Jun 2013
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Briocia Pharma (India )?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhay Kapse  | Director | Current | |
| Avinash Chandvankar | Director | 25-May-2011 | Current |
| Gopal Ramourti | Director | 21-Aug-2010 | Current |
Financial Performance and Corporate Structure Insights of Briocia Pharma (India ).
Enhance accessibility to Briocia Pharma (India )'s financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Briocia Pharma (India )?
Unlock access to Briocia Pharma (India )'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Jul 2010 | ₹26.73 Cr | Open |
Bank Of Maharashtra Creation Date: 07 Mar 2009 | ₹3.75 M | Satisfied |
Bank Of Maharashtra Creation Date: 12 Jan 2007 | ₹6.42 Cr | Satisfied |
How Many Employees Work at Briocia Pharma (India )?
Briocia Pharma (India ) has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Briocia Pharma (India ), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Briocia Pharma (India )'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
